Plain-English translation of NCT06160323 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial compares two ways to manage severe pain from pancreatic cancer that cannot be surgically removed. One group receives an early endoscopic ultrasound-guided nerve-blocking procedure (celiac ganglion or celiac plexus neurolysis) to block pain signals from the pancreas. The other group follows standard treatment guidelines, starting with stronger pain medications and only receiving the nerve-blocking procedure later if pain remains poorly controlled.
People with inoperable pancreatic cancer often suffer from severe, unrelenting pain that requires strong opioid medications, which can cause difficult side effects like nausea, drowsiness, and constipation. This trial exists to find out whether blocking the nerves that carry pain signals early in treatment might give patients better pain relief with fewer medication side effects.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. Both groups will first undergo an endoscopic ultrasound examination (a procedure where a thin tube with an ultrasound camera is passed down your throat to examine your pancreas). If assigned to the early nerve-blocking group, you will receive the procedure to block pain nerves during that same visit. If assigned to the standard care group, you will receive stronger pain medications as needed, and after 4 weeks, if your pain is not well controlled, you will have the option to receive the nerve-blocking procedure. You will be blinded, meaning you won't know which group you're in until after the study.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Hong Kong